DocMorris, a Swiss pharmaceutical company, has raised its full-year 2026 guidance following strong growth in prescription medicines and digital services in the first half of the year. Revenue from prescription medicines rose 38.3% in the first half, with the company now expecting full-year Rx growth of around 40%. Digital Services revenue jumped 71.4%, and EBITDA doubled, prompting the company to raise its full-year growth forecast for the business to more than 50%. The company has also narrowed its adjusted EBITDA loss forecast to 10 million-17.5 million francs and expects capital expenditure below 30 million francs.
Markets
